The endothelial dysfunction induced by hyperhomocysteinemia can be reversed by 5-methyltetrahydrofolate(5-MTHF) via homocysteine(Hcy)lowering. An additive antioxidant action of 5-MTHF has been suggested to ameliorate endothelial dysfunction through increased nitric oxide production and superoxide radical scavenging, independent of Hcy lowering. The aim of the study was to assess whether 5-MTHFaffects the redox state in hyperhomocysteinemia. We examined the effect of 3 months of oral 5-MTHF treatment (15 mg/day) on the redox pattern in 48 hyperhomocysteinemic subjects compared to 24 untreated hyperhomocysteinemic subjects. By analysis of variance with repeated measures in the 72 subjects,5-MTHF markedly decreased plasma total Hcy (p-tHcy; P=0.0001) and blood-total glutathione (GSH; b-tGSH; P=0.002). By multivariate linear regression in the treated subjects, p-tHcy changes from baseline to 3 months(adjusted by baseline p-tHcy levels) correlated only with changes in reduced cysteinylglycine (P=0.001). The effects of treatment on Hcy lowering and GSH metabolism were greater in medium than in moderate hyperhomocysteinemia. In conclusion, high-dose 5-MTHF treatment for 3 months ensures marked Hcy lowering to normal values even in subjects with high Hcy levels, and should be the treatment of choice in medium hyperhomocysteinemia. Furthermore, 5-MTHF shows a favorable interaction with GSH metabolism.
Effect of homocysteine lowering by 5-methyltetrahydrofolate on redox status in hyperhomocysteinemia
Campolo J;
2006
Abstract
The endothelial dysfunction induced by hyperhomocysteinemia can be reversed by 5-methyltetrahydrofolate(5-MTHF) via homocysteine(Hcy)lowering. An additive antioxidant action of 5-MTHF has been suggested to ameliorate endothelial dysfunction through increased nitric oxide production and superoxide radical scavenging, independent of Hcy lowering. The aim of the study was to assess whether 5-MTHFaffects the redox state in hyperhomocysteinemia. We examined the effect of 3 months of oral 5-MTHF treatment (15 mg/day) on the redox pattern in 48 hyperhomocysteinemic subjects compared to 24 untreated hyperhomocysteinemic subjects. By analysis of variance with repeated measures in the 72 subjects,5-MTHF markedly decreased plasma total Hcy (p-tHcy; P=0.0001) and blood-total glutathione (GSH; b-tGSH; P=0.002). By multivariate linear regression in the treated subjects, p-tHcy changes from baseline to 3 months(adjusted by baseline p-tHcy levels) correlated only with changes in reduced cysteinylglycine (P=0.001). The effects of treatment on Hcy lowering and GSH metabolism were greater in medium than in moderate hyperhomocysteinemia. In conclusion, high-dose 5-MTHF treatment for 3 months ensures marked Hcy lowering to normal values even in subjects with high Hcy levels, and should be the treatment of choice in medium hyperhomocysteinemia. Furthermore, 5-MTHF shows a favorable interaction with GSH metabolism.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
